Open AccessWhat makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology
Author(s) -
Dania Altulea,
Sjors Maassen,
Maksim V. Baranov,
Geert van den Bogaart
Publication year - 2021
Publication title -
journal of molecular cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.825
H-Index - 62
eISSN - 1759-4685
pISSN - 1674-2788
DOI - 10.1093/jmcb/mjab016
Subject(s) - hydroxychloroquine , chloroquine , repurposing , covid-19 , drug repositioning , pharmacology , clinical trial , medicine , biology , virology , disease , bioinformatics , immunology , drug , malaria , infectious disease (medical specialty) , outbreak , ecology
Since chloroquine (CQ) and hydroxychloroquine (HCQ) can inhibit the invasion and proliferation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cultured cells, the repurposing of these antimalarial drugs was considered a promising strategy for treatment and prevention of coronavirus disease (COVID-19). However, despite promising preliminary findings, many clinical trials showed neither significant therapeutic nor prophylactic benefits of CQ and HCQ against COVID-19. Here, we aim to answer the question of why these drugs are not effective against the disease by examining the cellular working mechanisms of CQ and HCQ in prevention of SARS-CoV-2 infections.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom